Literature DB >> 15004140

Myeloid differentiation factor 88 is required for cross-priming in vivo.

Deborah Palliser1, Hidde Ploegh, Marianne Boes.   

Abstract

We describe a role for myeloid differentiation factor 88 (MyD88) in the induction of functional CTLs in vivo, in response to exogenously administered Ag, using a heat shock fusion protein, hsp65-P1, as a model Ag. CD8 T cells transferred into MyD88-deficient animals produce normal numbers of CD8 effector cells that have normal activation marker profiles after immunization with hsp65-P1. However, these CD8 T cells produced significantly less IFN-gamma and showed reduced killing activity. This reduction in activation of functional CTLs appears to be unrelated to Toll-like receptor 4 function, because in vitro hsp65-P1-experienced Toll-like receptor 4-deficient dendritic cells (DCs), but not MyD88-deficient DCs, activated CD8 T cells to a similar extent to wild-type DCs. We identify a cross-presentation defect in MyD88-deficient DCs that, when treated with hsp65-P1 fusion protein, results in surface display of fewer SIYRYYGL/class I MHC complexes. Thus, MyD88 plays a role in the developmental maturation of DCs that allows them to prime CD8 T cells through cross-presentation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15004140     DOI: 10.4049/jimmunol.172.6.3415

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  16 in total

1.  MyD88 expression is required for efficient cross-presentation of viral antigens from infected cells.

Authors:  Margaret Chen; Christina Barnfield; Tanja I Näslund; Marina N Fleeton; Peter Liljeström
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

Review 2.  Recent advances in dendritic cell biology.

Authors:  Sylvia Adams; David W O'Neill; Nina Bhardwaj
Journal:  J Clin Immunol       Date:  2005-03       Impact factor: 8.317

Review 3.  Recent advances in dendritic cell biology.

Authors:  Sylvia Adams; David W O'Neill; Nina Bhardwaj
Journal:  J Clin Immunol       Date:  2005-05       Impact factor: 8.317

4.  Lymphocytic choriomeningitis virus (LCMV) infection of CNS glial cells results in TLR2-MyD88/Mal-dependent inflammatory responses.

Authors:  Shenghua Zhou; Annett Halle; Evelyn A Kurt-Jones; Anna M Cerny; Ermelinda Porpiglia; Michael Rogers; Douglas T Golenbock; Robert W Finberg
Journal:  J Neuroimmunol       Date:  2008-02       Impact factor: 3.478

Review 5.  Endosomal processing for antigen presentation mediated by CD1 and Class I major histocompatibility complex: roads to display or destruction.

Authors:  Marianne Boes; Arie J Stoppelenburg; Fenna C M Sillé
Journal:  Immunology       Date:  2009-06       Impact factor: 7.397

Review 6.  Natural killer cell activation by dendritic cells: balancing inhibitory and activating signals.

Authors:  Rosa Barreira da Silva; Christian Münz
Journal:  Cell Mol Life Sci       Date:  2011-08-23       Impact factor: 9.261

Review 7.  Antigen cross-presentation: extending recent laboratory findings to therapeutic intervention.

Authors:  T W H Flinsenberg; E B Compeer; J J Boelens; M Boes
Journal:  Clin Exp Immunol       Date:  2011-05-11       Impact factor: 4.330

8.  Toll-like receptor adaptor molecules enhance DNA-raised adaptive immune responses against influenza and tumors through activation of innate immunity.

Authors:  Fumihiko Takeshita; Toshiyuki Tanaka; Tomoko Matsuda; Miyuki Tozuka; Kouji Kobiyama; Sukumar Saha; Kiyohiko Matsui; Ken J Ishii; Cevayir Coban; Shizuo Akira; Norihisa Ishii; Koichi Suzuki; Dennis M Klinman; Kenji Okuda; Shin Sasaki
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

9.  MyD88 intrinsically regulates CD4 T-cell responses.

Authors:  Shenghua Zhou; Evelyn A Kurt-Jones; Anna M Cerny; Melvin Chan; Roderick Terry Bronson; Robert W Finberg
Journal:  J Virol       Date:  2008-12-03       Impact factor: 5.103

10.  Contrasting roles of the IL-1 and IL-18 receptors in MyD88-dependent contact hypersensitivity.

Authors:  Paul A Klekotka; Liping Yang; Wayne M Yokoyama
Journal:  J Invest Dermatol       Date:  2010-01       Impact factor: 8.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.